{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:58:25Z","timestamp":1789664305705,"version":"4.0.1"},"reference-count":46,"publisher":"Royal College of General Practitioners","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BJGP Open"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Fibromyalgia is a common cause of chronic pain in the UK, with a huge individual and societal impact. Despite this, it remains difficult to diagnose and treat. The explanation of a fibromyalgia diagnosis can lead to difficult therapeutic relationships, with attitudinal issues and negative profiling of patients. This can lead to frustration, and have a harmful impact on health outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To review how an explanation of a fibromyalgia diagnosis is provided in primary care in order to establish a model of best practice when educating patients on their diagnosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design &amp; setting<\/jats:title><jats:p>Scoping review of articles written in English.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>MEDLINE, Embase, Web of Science, and grey literature were searched. Articles were extracted, reviewed, and analysed according to the inclusion criteria.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 29 records met the inclusion criteria. The following six overarching themes were identified: patient education; physician education; importance of the multidisciplinary team; importance of patient-centred care; the value of primary care; and useful resources. The literature illustrated that describing fibromyalgia using analogies to illustrate the pain sensitisation process can help patients understand their diagnosis better. This improves their willingness to accept management plans, particularly engagement with non-pharmacological therapies, which the literature suggested are best delivered within a multidisciplinary team.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Key aspects of fibromyalgia should be explained to patients in order for them to gain a better understanding of their diagnosis. A 'one-size-fits-all' model for explaining the fibromyalgia diagnosis to patients is inappropriate because patients' experiences are individualised. Further research is required on whether different explanations impact patient outcomes.<\/jats:p><\/jats:sec>","DOI":"10.3399\/bjgpo.2023.0033","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T15:55:19Z","timestamp":1689782119000},"page":"BJGPO.2023.0033","source":"Crossref","is-referenced-by-count":4,"title":["Explaining a diagnosis of fibromyalgia in primary care: a scoping review"],"prefix":"10.3399","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2518-2897","authenticated-orcid":false,"given":"Kerrie","family":"McConnell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4123-9806","authenticated-orcid":false,"given":"Neil","family":"Heron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel D","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1987","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"key":"2023121918050877000_7.4.BJGPO.2023.0033.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32154-2"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010364"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.3","unstructured":"Public Health England (2021) Chronic pain in adults 2017. accessed. www.gov.uk\/government\/publications\/chronic-pain-in-adults-2017. 23 Oct 2023."},{"issue":"2","key":"2023121918050877000_7.4.BJGPO.2023.0033.4","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/art.38905","article-title":"The prevalence of fibromyalgia in the general population: a comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria","author":"Jones","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.02.010"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.6","unstructured":"National Institute for Health and Care Excellence (2021) Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain. NG193. accessed. https:\/\/www.nice.org.uk\/guidance\/ng193. 23 Oct 2023."},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.7","unstructured":"Royal College of Physicians (2022) The diagnosis of fibromyalgia syndrome. accessed. www.rcplondon.ac.uk\/guidelines-policy\/diagnosis-fibromyalgia-syndrome. 23 Oct 2023."},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00392-5"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.24922"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.10","doi-asserted-by":"publisher","DOI":"10.1177\/21501327211031767"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.11","doi-asserted-by":"publisher","DOI":"10.1177\/1742395317718035"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209724"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.13","unstructured":"Kay L Lanyon P MacGregor A (2021) Rheumatology: GIRFT programme national specialty report. accessed. https:\/\/www.gettingitrightfirsttime.co.uk\/wp-content\/uploads\/2021\/08\/Rheumatology-Jul21h-NEW.pdf. 23 Oct 2023."},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.14","doi-asserted-by":"publisher","DOI":"10.1080\/1364557032000119616"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.15","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-5-69"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.16","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0850"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.17","unstructured":"Canadian Agency for Drugs and Technologies in Health (2022) Grey matters: a tool for searching health-related grey literature. accessed. https:\/\/greymatters.cadth.ca. 23 Oct 2023."},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.18","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.19","doi-asserted-by":"publisher","DOI":"10.46658\/JBIRM-190-01"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.20","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4521389"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.21","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-022-05284-y"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.22","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.1738"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-046943"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.enfcli.2017.08.008"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.25","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/18.1.60"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.26","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e31820b131c"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0738-3991(02)00095-2"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.28","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/354868"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2010.09.006"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.30","doi-asserted-by":"publisher","DOI":"10.1111\/papr.12137"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.31","doi-asserted-by":"publisher","DOI":"10.1080\/09638280600949860"},{"issue":"1","key":"2023121918050877000_7.4.BJGPO.2023.0033.32","first-page":"98","article-title":"A Psychoeducational intervention is a treatment for fibromyalgia syndrome","author":"Conversano","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.33","doi-asserted-by":"publisher","DOI":"10.1080\/20786204.2006.10873355"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.pop.2010.07.007"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.35","doi-asserted-by":"publisher","DOI":"10.1053\/berh.1999.0037"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.36","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2018.1411743"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.37","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aet351"},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.38","unstructured":"Northern Health and Social Care Trust (NHSCT) (2017) Fibromyalgia diagnostic and management pathway (Antrim: NHSCT)."},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.39","unstructured":"NHS Greater Glasgow and Clyde (2022) Managing fibromyalgia syndrome in primary care. accessed. https:\/\/www.nhsggc.org.uk\/media\/253779\/managing-fibromyalgia-syndrome-in-primary-care.pdf. 30 Oct 2023."},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.40","unstructured":"American College of Rheumatology (2023) Fibromyalgia. accessed. https:\/\/www.rheumatology.org\/I-Am-A\/Patient-Caregiver\/Diseases-Conditions\/Fibromyalgia. 23 Oct 2023."},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.41","unstructured":"Versus Arthritis (2020) Fibromyalgia. accessed. https:\/\/www.versusarthritis.org\/media\/24901\/fibromyalgia-information-booklet-july2021.pdf. 23 Oct 2023."},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.42","unstructured":"Centers for Disease Control and Prevention (2020) Fibromyalgia. accessed. https:\/\/www.cdc.gov\/arthritis\/basics\/fibromyalgia.htm. 23 Oct 2023."},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.43","unstructured":"Fibromyalgia Action UK (2016) Information booklet for people affected by fibromyalgia. accessed. https:\/\/www.fmauk.org\/dmdocuments\/FMAUKInformationBooklet.pdf. 23 Oct 2023."},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.44","unstructured":"MayoClinic (2021) Fibromyalgia. accessed. https:\/\/www.mayoclinic.org\/diseases-conditions\/fibromyalgia\/symptoms-causes\/syc-20354780. 23 Oct 2023."},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.45","unstructured":"NHS (2022) Fibromyalgia. accessed. https:\/\/www.nhs.uk\/conditions\/fibromyalgia. 23 Oct 2023."},{"key":"2023121918050877000_7.4.BJGPO.2023.0033.46","doi-asserted-by":"publisher","DOI":"10.1191\/1478088706qp063oa"}],"container-title":["BJGP Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3399\/BJGPO.2023.0033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T02:09:24Z","timestamp":1703038164000},"score":1,"resource":{"primary":{"URL":"http:\/\/bjgpopen.org\/lookup\/doi\/10.3399\/BJGPO.2023.0033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":46,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,12,19]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.3399\/BJGPO.2023.0033"],"URL":"https:\/\/doi.org\/10.3399\/bjgpo.2023.0033","relation":{},"ISSN":["2398-3795"],"issn-type":[{"value":"2398-3795","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,19]]}}}